Esperion Therapeutics, Inc. Reports Second Quarter Financial Results and Provides Corporate Update
8/12/2013 6:53:32 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided a corporate update and reported its financial results for the second quarter ended June 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by